Skip to main content
Top
Published in: Journal of Gastroenterology 3/2023

30-12-2022 | Hepatic Encephalopathy | Original Article―liver, Pancreas, and Biliary Tract

A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension

Authors: Tsuyoshi Ishikawa, Maho Egusa, Tsuyoshi Fujioka, Natsuko Nishiyama, Daiki Kawamoto, Ryo Sasaki, Tatsuro Nishimura, Norikazu Tanabe, Takashi Oono, Issei Saeki, Taro Takami

Published in: Journal of Gastroenterology | Issue 3/2023

Login to get access

Abstract

Background

We previously reported liver stiffness (LS) as a prognostic predictor of portosystemic shunt (PSS) occlusion. This study aims to reinvestigate the predictive factors of the model for end-stage liver disease-sodium (MELD-Na) score amelioration following balloon-occluded retrograde transvenous obliteration (BRTO) and to evaluate the postoperative prognoses of patients with portal hypertension by using newly identified factors.

Methods

Seventy-five patients who underwent BRTO between 2008 and 2021 were retrospectively enrolled. The MELD-Na scores were calculated preoperatively and one month postoperatively. We monitored long-term outcomes and analyzed postoperative survival.

Results

At one month postoperatively, the MELD-Na score decreased in 46 (61.3%) patients. Univariate analyses revealed a significant association of the score amelioration with nine factors, including lower LS levels and a higher international normalized ratio (INR). A multivariate logistic regression analysis with receiver operating characteristic curve analyses identified preoperative LS levels and INR as significant independent predictors of the postoperative MELD-Na score amelioration, with optimal cutoffs of 28.1 kPa and 1.06, respectively. The combination of LS < 28.1 kPa and INR ≥ 1.06 showed a sensitivity and specificity of 84.8% and 75.9% for the prediction of the score amelioration, respectively. For the propensity score model, we matched 24 patients with similar age, sex, MELD-Na score, and concomitant hepatocellular carcinoma. Kaplan–Meier analysis determined significantly higher cumulative survival rates in patients with LS < 28.1 kPa and INR ≥ 1.06 than in other populations.

Conclusions

A combination of LS and INR can predict the MELD-Na score amelioration and prognosis improvement following PSS occlusion.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kanagawa H, Mima S, Kouyama H, et al. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 1996;11:51–8.CrossRefPubMed Kanagawa H, Mima S, Kouyama H, et al. Treatment of gastric fundal varices by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 1996;11:51–8.CrossRefPubMed
2.
go back to reference Hirota S, Matsumoto S, Tomita M, et al. Retrograde transvenous obliteration of gastric varices. Radiology. 1999;211:349–56.CrossRefPubMed Hirota S, Matsumoto S, Tomita M, et al. Retrograde transvenous obliteration of gastric varices. Radiology. 1999;211:349–56.CrossRefPubMed
3.
go back to reference Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol. 2001;12:327–36.CrossRefPubMed Fukuda T, Hirota S, Sugimura K. Long-term results of balloon-occluded retrograde transvenous obliteration for the treatment of gastric varices and hepatic encephalopathy. J Vasc Interv Radiol. 2001;12:327–36.CrossRefPubMed
4.
go back to reference Akahane T, Iwasaki T, Kobayashi N, et al. Changes in liver function parameters after occlusion of gastrorenal shunts with balloon-occluded retrograde transvenous obliteration. Am J Gastroenterol. 1997;92:1026–30.PubMed Akahane T, Iwasaki T, Kobayashi N, et al. Changes in liver function parameters after occlusion of gastrorenal shunts with balloon-occluded retrograde transvenous obliteration. Am J Gastroenterol. 1997;92:1026–30.PubMed
5.
go back to reference Hirota S, Kobayashi K, Maeda H, et al. Balloon-occluded retrograde transvenous obliteration for portal hypertension. Radiat Med. 2006;24:315–20.CrossRefPubMed Hirota S, Kobayashi K, Maeda H, et al. Balloon-occluded retrograde transvenous obliteration for portal hypertension. Radiat Med. 2006;24:315–20.CrossRefPubMed
6.
go back to reference Kumamoto M, Toyonaga A, Inoue H, et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: hepatic deterioration links to portosystemic shunt syndrome. J Gastroenterol Hepatol. 2010;25:1129–35.CrossRefPubMed Kumamoto M, Toyonaga A, Inoue H, et al. Long-term results of balloon-occluded retrograde transvenous obliteration for gastric fundal varices: hepatic deterioration links to portosystemic shunt syndrome. J Gastroenterol Hepatol. 2010;25:1129–35.CrossRefPubMed
7.
go back to reference Naeshiro N, Aikata H, Kakizawa H, et al. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 2014;29:1035–42.CrossRefPubMed Naeshiro N, Aikata H, Kakizawa H, et al. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration. J Gastroenterol Hepatol. 2014;29:1035–42.CrossRefPubMed
8.
go back to reference Imai Y, Nakazawa M, Ando S, et al. Long-term outcome of 154 patients receiving balloon-occluded retrograde transvenous obliteration for gastric fundal varices. J Gastroenterol Hepatol. 2016;31:1844–50.CrossRefPubMed Imai Y, Nakazawa M, Ando S, et al. Long-term outcome of 154 patients receiving balloon-occluded retrograde transvenous obliteration for gastric fundal varices. J Gastroenterol Hepatol. 2016;31:1844–50.CrossRefPubMed
9.
go back to reference Yamamoto A, Nishida N, Morikawa H, et al. Prediction for improvement of liver function after balloon-occluded retrograde transvenous obliteration for gastric varices to manage portosystemic shunt syndrome. J Vasc Interv Radiol. 2016;27:1160–7.CrossRefPubMed Yamamoto A, Nishida N, Morikawa H, et al. Prediction for improvement of liver function after balloon-occluded retrograde transvenous obliteration for gastric varices to manage portosystemic shunt syndrome. J Vasc Interv Radiol. 2016;27:1160–7.CrossRefPubMed
10.
go back to reference Ishikawa T, Sasaki R, Nishimura T, et al. Liver stiffness measured by transient elastography as predictor of prognoses following portosystemic shunt occlusion. J Gastroenterol Hepatol. 2019;34:215–23.CrossRefPubMed Ishikawa T, Sasaki R, Nishimura T, et al. Liver stiffness measured by transient elastography as predictor of prognoses following portosystemic shunt occlusion. J Gastroenterol Hepatol. 2019;34:215–23.CrossRefPubMed
11.
go back to reference de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959–74.CrossRefPubMed de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII—renewing consensus in portal hypertension. J Hepatol. 2022;76:959–74.CrossRefPubMed
12.
go back to reference Ishikawa T, Shiratsuki S, Matsuda T, et al. Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension. J Gastroenterol. 2014;49:1333–41.CrossRefPubMed Ishikawa T, Shiratsuki S, Matsuda T, et al. Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension. J Gastroenterol. 2014;49:1333–41.CrossRefPubMed
13.
go back to reference Ishikawa T, Aibe Y, Matsuda T, et al. Plasma glucose level is predictive of serum ammonia level after retrograde occlusion of portosystemic shunts. AJR Am J Roentgenol. 2017;209:W169–76.CrossRefPubMed Ishikawa T, Aibe Y, Matsuda T, et al. Plasma glucose level is predictive of serum ammonia level after retrograde occlusion of portosystemic shunts. AJR Am J Roentgenol. 2017;209:W169–76.CrossRefPubMed
14.
go back to reference Ishikawa T, Sasaki R, Nishimura T, et al. Comparison of patients with hepatic encephalopathy and those with gastric varices before and after balloon-occluded retrograde transvenous obliteration. Hepatol Res. 2018;48:1020–30.CrossRefPubMed Ishikawa T, Sasaki R, Nishimura T, et al. Comparison of patients with hepatic encephalopathy and those with gastric varices before and after balloon-occluded retrograde transvenous obliteration. Hepatol Res. 2018;48:1020–30.CrossRefPubMed
15.
go back to reference Ishikawa T, Sasaki R, Nishimura T, et al. Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism. J Gastroenterol. 2021;56:382–94.CrossRefPubMed Ishikawa T, Sasaki R, Nishimura T, et al. Splenic non-infarction volume determines a clinically significant hepatic venous pressure gradient response to partial splenic embolization in patients with cirrhosis and hypersplenism. J Gastroenterol. 2021;56:382–94.CrossRefPubMed
16.
go back to reference Yeh WC, Li PC, Jeng YM, et al. Elastic modulus measurements of human liver and correlation with pathology. Ultrasound Med Biol. 2002;28:467–74.CrossRefPubMed Yeh WC, Li PC, Jeng YM, et al. Elastic modulus measurements of human liver and correlation with pathology. Ultrasound Med Biol. 2002;28:467–74.CrossRefPubMed
17.
go back to reference The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 6th ed. Tokyo: Kanehara; 2015. The Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. 6th ed. Tokyo: Kanehara; 2015.
18.
go back to reference Kudo M, Kitano M, Sakurai T, et al. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the liver cancer study group of Japan. Dig Dis. 2015;33:765–70.CrossRefPubMed Kudo M, Kitano M, Sakurai T, et al. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the liver cancer study group of Japan. Dig Dis. 2015;33:765–70.CrossRefPubMed
19.
go back to reference Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985;5:419–24.CrossRefPubMed Garcia-Tsao G, Groszmann RJ, Fisher RL, et al. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology. 1985;5:419–24.CrossRefPubMed
20.
go back to reference Ripoll C, Groszmann R, Garcia-Tsao G, et al. Portal hypertension collaborative group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481–8.CrossRefPubMed Ripoll C, Groszmann R, Garcia-Tsao G, et al. Portal hypertension collaborative group. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481–8.CrossRefPubMed
21.
go back to reference Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923–8.CrossRefPubMedPubMedCentral Ripoll C, Groszmann RJ, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol. 2009;50:923–8.CrossRefPubMedPubMedCentral
22.
go back to reference de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.CrossRefPubMed de Franchis R. Expanding consensus in portal hypertension: report of the Baveno VI consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.CrossRefPubMed
23.
go back to reference Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82.CrossRefPubMed Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82.CrossRefPubMed
24.
go back to reference Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007;45:1290–7.CrossRefPubMed Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007;45:1290–7.CrossRefPubMed
26.
go back to reference Ishikawa T, Sasaki R, Nishimura T, et al. Improved hepatic reserve and fibrosis in a case of “portal-systemic liver failure” by portosystemic shunt occlusion. Am J Case Rep. 2020;21: e921236.CrossRefPubMedPubMedCentral Ishikawa T, Sasaki R, Nishimura T, et al. Improved hepatic reserve and fibrosis in a case of “portal-systemic liver failure” by portosystemic shunt occlusion. Am J Case Rep. 2020;21: e921236.CrossRefPubMedPubMedCentral
27.
go back to reference Wood AJ, Villeneuve JP, Branch RA, et al. Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat. Gastroenterology. 1979;76:1358–62.CrossRefPubMed Wood AJ, Villeneuve JP, Branch RA, et al. Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat. Gastroenterology. 1979;76:1358–62.CrossRefPubMed
28.
go back to reference Kawasaki S, Imamura H, Bandai Y, et al. Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis. Gastroenterology. 1992;102:1351–5.CrossRefPubMed Kawasaki S, Imamura H, Bandai Y, et al. Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis. Gastroenterology. 1992;102:1351–5.CrossRefPubMed
Metadata
Title
A combination of liver stiffness and international normalized ratio is an ideal prognostic predictor of portosystemic shunt occlusion in patients with portal hypertension
Authors
Tsuyoshi Ishikawa
Maho Egusa
Tsuyoshi Fujioka
Natsuko Nishiyama
Daiki Kawamoto
Ryo Sasaki
Tatsuro Nishimura
Norikazu Tanabe
Takashi Oono
Issei Saeki
Taro Takami
Publication date
30-12-2022
Publisher
Springer Nature Singapore
Published in
Journal of Gastroenterology / Issue 3/2023
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-022-01947-8

Other articles of this Issue 3/2023

Journal of Gastroenterology 3/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.